Insulin vitamin D conjugates
AssigneeExtend Biosciences, Inc.
InventorsTarik Soliman, Laura M. Hales, Daniel B. Hall, Howard Sard, Vishnumurthy Hegde
Life of this patent
Estimating the term…
Abstract
The invention provides non-hormonal vitamin D conjugated to insulin peptides that result in the peptides having increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. The vitamin D targeting groups are coupled to the insulin peptides via the third carbon on the vitamin D backbone.
Claims20
A method of treating a patient in need of insulin, comprising administering an effective amount of a pharmaceutical composition comprising said insulin conjugated to the carbon 3 position of a non-hormonal vitamin D targeting group that is not hydroxylated at the carbon 1 position.
A pharmaceutical carrier comprising a formula I:
- B-(L)-a S-(M)-b-C I
- Wherein:
- B is a targeting group that is a vitamin D that is not hydroxylated at the carbon 1 position, conjugated at the carbon 3 position to (L)a ;
- S is a scaffold moiety, comprising poly(ethylene glycol), polylysine, polyethyleneimine, poly(propyleneglycol), a peptide, an amino acid, a nucleic acid, a glycan, a modifying group that contains a reactive linker, polylactic acid, a water-soluble polymer, a small carbon chain linker, or an additional therapeutic moiety;
- C is an amine-reactive group, a thiol-reactive group, a maleimide group, a thiol group, a disulfide group, an aldehyde group, an NETS-ester group, a 4-nitrophenyl ester, an acylimidazole, a haloacetyl group, an iodoacetyl group, a bromoacetyl groups, a SMCC group, a sulfo SMCC group, a carbodiimide group and bifunctional cross-linkers such as NHS-Maleimido or combinations thereof;
- (L)a and (M)b are linkers independently selected from —(CH2)n—, —C(O)NH—, —HNC(O)—, —C(O)O—, —OC(O)—, —O—, —S—S—, —S—, —S(O)—, —S(O)2— and —NH—;
- a is an integer from 0-4;
- b is an integer from 0-4;
- and
- n is an integer from 0-3.
Dependencies are inferred from the claim text.